

# ACMD

## Advisory Council on the Misuse of Drugs

---

ACMD Chair: Professor Owen Bowden-Jones  
Synthetic Cathinones Working Group Secretary: Lydia Chaloner  
1<sup>st</sup> Floor (NE), Peel Building  
2 Marsham Street  
London  
SW1P 4DF  
[ACMD@homeoffice.gov.uk](mailto:ACMD@homeoffice.gov.uk)

Tuesday 14<sup>th</sup> May 2024

Dear Sir or Madam,

### **RE: Call for Evidence – Synthetic Cathinones**

The Novel Psychoactive Substances Committee (NPSC) of the Advisory Council on the Misuse of Drugs (ACMD) is currently reviewing the evidence of the misuse and harms of synthetic cathinones in the United Kingdom, as requested by Government. The report aims to consider the evidence regarding the current use and harms of synthetic cathinones in the UK.

The ACMD would be grateful for your written feedback by **31<sup>st</sup> May 2024**, using the attached questionnaire as part of a public call for evidence. We welcome submissions of evidence from as broad a spectrum of participants as possible and would be grateful if you could please circulate this call for evidence to other colleagues and relevant stakeholders. The ACMD will use this evidence to assist in formulating advice to Government.

Thank you in advance for your assistance. If you have any questions or concerns about this call for evidence, please feel free to get in touch with us using the above email address.

Yours sincerely,



Professor Owen Bowden-Jones  
**Chair of ACMD**



Professor Simon Thomas  
**Chair of NPS Committee**

# ACMD Synthetic Cathinones Review – Call For Evidence

**Please consider the following information before completing the questionnaire:**

## Completing the questionnaire

Although your expertise may be better suited to tackling only a subset of the following questions, it would be helpful if you were to consider every question in the questionnaire.

Where possible, please provide supporting evidence and references in your response. The ACMD considers a wide range of evidence as part of its advice, including published literature, statistics, data from UK organisations and expert and stakeholder opinions.

**Please return your submission to the ACMD Secretariat at:**

[acmd@homeoffice.gov.uk](mailto:acmd@homeoffice.gov.uk).

## How we will use your information

Respondents should note that evidence submitted will inform the development of recommendations from the ACMD and could ultimately be published. However, in the interest of confidentiality and protecting commercial interests, any information submitted will be non-attributable.

All data submitted in response to this call for evidence will be protected by the ACMD Secretariat in accordance with the UK General Data Protection Regulation (UK GDPR). Furthermore, Section 43(1) of the Freedom of Information Act provides an exemption for information which is a trade secret, whilst Section 43(2) exempts information whose disclosure would, or would be likely to, prejudice the commercial interests of any person (an individual, a company, the public authority itself or any other legal entity).

## **Section 1: About yourself / your organisation**

**Q1. Please indicate below if the following statement is applicable:**

- “My submission should be considered a personal response reflecting my professional experience in this area and therefore not representative of the organisation I work for.”
- “My submission should be considered as representative of the organisation I work for.”

**Q2. Please describe either the nature of your organisation or your personal expertise within this area:**

Click or tap here to enter text.

## Section 2: Points of Interest

**Q1) Are synthetic cathinones (eg: mephedrone, clephedrone, MDPHP ('monkey dust'), alpha-PHP and alpha-PVP) a problem where you live or work? If they are, please state where and explain the extent and nature of the problem.**

Click or tap here to enter text.

**Q2) In your professional opinion, are there any specific cathinones (eg: mephedrone, clephedrone, MDPHP ('monkey dust'), alpha-PHP and alpha-PVP) which are of concern in the community in which you live or work? Please outline the concerns that come to your professional attention.**

Click or tap here to enter text.

**Q3) Which populations in the community are most affected by synthetic cathinone use and what impacts are cathinones having upon these populations? (Please refer to the details from Section 3 of the [ACMD Standard Operating Procedure](#))**

Click or tap here to enter text.

**Q4) Please outline any social or health harms arising from synthetic cathinone use within your local area or workplace.**

Click or tap here to enter text.

**Q5) Can you provide examples of interventions employed within your local area or workplace to address cathinone use (eg: drug treatment programmes)? If so, what evidence is there of the effectiveness of these interventions (eg: formal evaluations)?**

Click or tap here to enter text.